ArticleBMC cancer2026

The 30% reduction of baseline CA19-9 could stratify the prognosis of advanced pancreatic ductal adenocarcinoma with RECIST stable disease after first-line chemotherapy.

Xin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.